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Abstract
Migraine is a prevalent neurological disorder, affecting over 16% of adult women and 7% of adult 
men in the U.S., causing significant pain, disability, and medical expense, with incomplete benefits 
from conventional medical management. Migraine, as a chronic pain syndrome, provides a 
practical model for investigating the impact of dietary modifications in omega-3 (n-3) and 
omega-6 (n-6) fatty acids. This paper reports the protocol of a trial to assess whether targeted 
dietary modifications designed to increase n-3 eicosapentaenoic acid (EPA) and docosahexaenoic 
acid (DHA), with or without concurrent reduction in n-6 linoleic acid (LA), will alter nociceptive 
lipid mediators and mediate decreases in frequency and severity of migraine. This prospective, 
randomized, controlled trial in 153 male and female adult subjects, ages 18–99, with diagnosed 
and actively managed episodic migraine tests the efficacy, safety, and biochemical effects of 
targeted, controlled alterations in dietary omega-3 and omega-6 fatty acids. Participants are 
masked to diet hypotheses and all assessors are masked to treatment assignment. Following a four-
week baseline period, participants with migraine headache frequency of 5–20 per month are 
randomized to one of three intensive dietary regimens for 16 additional weeks followed by a less 
intensive observation period. Dietary intervention arms include: 1) increased n-3 EPA+DHA with 
low n-6 linoleic acid (H3 L6); 2) increased n-3 EPA+DHA with usual US dietary intake of n-6 
linoleic acid (H3 H6); and 3) usual US dietary content of n-3 and n-6 fatty acids (L3 H6). During 
the actual intervention, subjects receive content-specific study oils and foods sufficient for two 
meals and two snacks per day, as well as dietary counseling. Biochemical and clinical outcome 
measures are performed at intervals throughout this period. This randomized controlled trial is 
designed to determine whether targeted alterations in dietary n-3 and n-6 fatty acids can alter 
nociceptive lipid mediators in a manner that decreases headache pain and enhances quality of life 
and function in adults with frequent migraines.
Trial registration: NCT02012790
Keywords
Migraine; Omega-3; Omega-6; Linoleic acid; Lipid mediator; Oxylipin; pain; Headache; Diet; 
RCT
1. Introduction
Migraine is a common cause of chronic pain and the most prevalent neurologic disorder, 
[1,2] affecting over 16% of adult women and 7% of adult men. It is a major cause of 
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disability in the U.S., with loss of work and medical expenses adding up to billions of 
dollars per year [1]. Patients with migraine often receive only limited benefit from 
conventional medical management. While abortive therapy for acute migraine has improved 
substantially [2], preventative strategies—particularly for patients with more frequent 
headaches—often provide only modest benefit [3]. Conventional treatments rely heavily on 
medications that may provide only limited or transient relief, target symptoms rather than 
addressing the underlying causes of pain, and are associated with significant negative side 
effects and costs [4–11]. Medication side effects include medication overuse syndromes, as 
well as weight gain, fatigue, alopecia, tremor, constipation, cognitive impairment, and 
depression [1,5,8–10,12].
Migraine provides a practical model for investigating causes and treatments for chronic 
pathological pain syndromes because it shares underlying biochemical mechanisms with 
other chronic pain syndromes, such as peripheral and central sensitization [13], as well as 
neurologic features such as autonomic (flushing, chills, etc.), gastrointestinal (nausea, 
vomiting, diarrhea), sensory (photophobia, phonophobia, osmophobia and allodynia) and 
cognitive changes [14]. In addition, migraine is an extensively researched clinical condition 
with reliable self-report measures that are sensitive to change with treatment[15].
1.1. Dietary modulation of nociceptive mediators and physical pain
N-6 and n-3 fatty acids regulate multiple inflammation and pain-related biochemical 
pathways as major components of meninges, myelin, glia, skeletal muscle, and neuronal cell 
membranes [16]. N-6 and n-3 fatty acids can be converted to lipid mediators with pro- and 
anti-nociceptive properties (e.g. prostanoids [17], octadecanoids [18–20], endocannabinoids 
[21], n-3 monoepoxides [22], and resolvins [23–25]). With a few notable exceptions (e.g. 
lipoxins and epoxyeicosatrienoic acids), lipid mediators derived from n-6 fatty acids have 
pro-nociceptive properties, while mediators derived from n-3 fatty acids have anti-
nociceptive and pro-resolvin properties [17–24].
Our preliminary study, in a chronic daily headache (CDH) population (in which 88% of 
subjects had either chronic migraine or mixed headache with significant migraine features) 
sought to establish the feasibility and preliminary efficacy of targeted reductions in dietary 
n-6 LA, with and without concurrent increases in n-3 EPA and DHA. Results from this two 
armed, randomized pilot trial, with 67 CDH patients, demonstrated the feasibility of using 
intensive dietitian support and food provision in community dwelling patients to elicit 
targeted changes in dietary n-6 and n-3 fatty acids [26], and that the targeted changes in 
dietary intakes, erythrocyte fatty acids, and nociceptive lipid mediators could be achieved. 
Moreover, the high n-3 EPA + DHA, low n-6 LA (H3-L6) diet intervention produced a large, 
statistically significant and clinically-relevant improvement in headache frequency, intensity 
and other clinical outcomes compared to baseline, and compared to the Low n-6 only (L6) 
group. Those clinical effects were accompanied by statistically significant reductions in 
vasoactive abortive medication use, as well as total use of acute and adjunctive medications. 
The H3-L6 intervention produced marked increases in anti-nociceptive derivatives of EPA 
and DHA, and significant reductions in pronociceptive derivatives of n-6 LA and AA, while 
the L6 group had comparatively modest, but statistically significant biochemical changes 
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and improvement in headache-related clinical outcomes compared to baseline. However, 
these changes were significantly weaker than those seen in subjects undergoing the 
combined H3-L6 intervention [27].
In the previous study, both trial arms involved lowering of dietary n-6 LA to about 2.5% of 
calories, a level not usually found in modern U.S. diets. The current study seeks to examine 
the role that dietary n-6 LA lowering may play in the observed biochemical and clinical 
effects and to clarify the effects that can be achieved by increasing dietary EPA+DHA alone, 
without concurrent LA lowering. It is essential to determine whether LA lowering is 
necessary for clinical benefit since LA lowering is challenging in a U.S. population due to 
widespread addition of LA to packaged and restaurant foods. In the current, three-armed 
RCT, we address this knowledge gap by 1) comparing the effects of a H3-L6 intervention to 
a High n-3 intervention without a concurrent reduction in n-6 LA (H3-H6); 2) adding a 
control group consuming average U.S. amounts of n-3 and n-6 fatty acids (L3-H6). We also 
extend the active intervention phase to 16 weeks to determine the longer-term biochemical 
and clinical effects of these interventions.
2. Materials and methods
2.1. Study aims
This is a 3-arm, parallel-group, randomized, controlled 16-week trial to evaluate the 
biochemical effects and therapeutic efficacy of two dietary interventions in patients with 
episodic migraine compared with a control diet group.
The project’s primary objective is to assess whether targeted dietary modifications designed 
to increase dietary n-3 EPA and DHA, with or without concurrent reduction in n-6 LA, can 
increase analgesic derivatives of n-3 EPA and DHA, and improve headache-related clinical 
outcomes. This modified double-blind randomized controlled trial design will randomize 
153 participants to one of three 16-week dietary interventions:
Diet A: High n-3 EPA+DHA, Low n-6 LA (H3-L6) (See Preliminary Data)
Diet B: High n-3 EPA+DHA, High n-6 LA (H3-H6)
Diet C: Low n-3 EPA+DHA, High n-6 LA (L3-H6, average U.S. in-take; control 
group)
Target intakes of n-3 EPA+DHA and n-6 LA for each diet are provided in Table 1. The 
control amounts of LA (7.2% of energy (%E), Diet B and Diet C) and EPA+DHA (150 mg 
per 200 cal, Diet C) are comparable to average US intakes of these nutrients. The target dose 
selected for lowering of dietary LA (1.8%E, Diet A) was selected to be consistent with 
estimated intakes in historical diets comprised of un-processed foods prior to the widespread 
addition of seed oils in industrialized diets. The target for increasing EPA+DHA (to 1500 mg 
per 2000 cal, Diet A and Diet B) was selected based on the levels that were achievable in our 
pilot study [27]; these intakes resulted in major biochemical changes and appear to have 
reduced pain.
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Specific Aim 1. is to assess the efficacy of the dietary interventions in inducing the predicted 
changes in circulating n-3 and n-6 derivatives.
Hypothesis 1. (1a) Compared to Diet C, Diet A will produce significant increases in anti-
nociceptive derivatives of n-3 EPA and DHA (Primary Biochemical Outcome, 17-hydroxy 
DHA) and reductions in pronociceptive n-6 AA-derived and LA-derived mediators. (1b) 
Diet B (High n-3, High n-6 LA) will result in values for n-3 and n-6 derivatives intermediate 
between Diet A and Diet C.
Specific Aim 2. is to compare the clinical efficacy of the dietary interventions in adults with 
migraine.
Hypothesis 2. (2a) Compared to Diet C, Diet A will produce significant improvement in the 
Headache Impact Test score—a headache-specific quality of life measure (Primary Clinical 
Outcome). (2b) Additionally, as measured in the daily Headache Diary, Diet A will result in 
a significantly steeper rate of decrease in headache hours per day as compared with Diet C. 
(2c) Diet B will result in changes in clinical outcomes intermediate between Diet A and Diet 
C.
A secondary objective, Specific Aim 3, is to test our model of the proposed causal chain 
(Fig. 4) linking changes in n-3 and n-6 fatty acids and their bioactive derivatives to headache 
endpoints.
Hypothesis 3. (3a) Increases in erythrocyte and free fatty acid n-3 EPA and DHA and (3b) 
their anti-nociceptive derivatives will be positively associated with improvement in 
headache-specific quality-of-life and mean headache hours per day; (3c) reductions in n-6 
LA and AA, and (3d) their pro-nociceptive derivatives will be positively associated with 
headache-specific quality-of-life and mean headache hours per day.
2.2. Overview of recruitment and study procedures
Ethics approval for the study was provided by the Human Research Ethics Committee of the 
University of North Carolina (IRB# 13–3284), and all participants have provided written 
informed consent.
Approximately 2250 patients with episodic migraine are being recruited from central North 
Carolina clinics and practices, including headache clinics. Self-referrals are accepted unless 
the patient is not under the care of a physician who is managing headaches. Physicians in the 
community are informed of the study by direct contact and informational handouts so that 
they may inform their patients of the study and provide them with contact information 
and/or permission to have members of the research team contact them.
Potential participants are screened to achieve a pre-intervention sample size of a minimum 
of 51 subjects per group for each of the three study arms. We expect at least 42 of the 51 in 
each group to complete the 16-week intervention, which will provide adequate power to test 
both the primary clinical and biochemical aims (Specific Aims 1 and 2).
Mann et al. Page 5













In addition to history, physical examination, and documentation of inclusion criteria, 
participants complete baseline assessment instruments that measure headache characteristics 
and their impact on quality-of-life. Participants who are compliant with all aspects of data 
collection, and who experience migraine headaches between 5 and 20 days per month, are 
eligible for the study. After an initial 4- to 6-week baseline phase for monitoring usual 
dietary intake, diary adherence, and headache characteristics, 153 participants are planned to 
be randomized to 1 of the 3 study diets (Table 1, Fig. 1), to be maintained for 16 consecutive 
weeks. All participants will continue to receive usual medical care for their headaches 
throughout the 4- to 6-week baseline phase, and the 16-week intervention period. Eligibility 
is based on inclusion and exclusion criteria (Table 2).
2.2.1. Participant flow—At the end of the baseline phase, participants who qualify are 
randomized to one of the following arms: 1) High n-3, Low n-6 (H3-L6) Diet A; 2) High 
n-3, High n-6 (H3-H6) Diet B; or 3) the Low n-3, High n-6 (L3-H6) Diet C. After 
randomization, participants attend an initial, in-depth dietary counseling session 
administered by the registered dietitian. Participants receive detailed instruction in the 
specific dietary intervention per group assignment. Participants in each group attend five 
blood draw visits and six follow-up sessions with the dietitian. At each visit, the dietitian 
reviews and records dietary adherence per diet history, daily food checklists and subject self-
report, assesses diet education needs, provides tailored diet counseling and dispenses 
research food supply. Visits occur every 2 weeks for the first 4 weeks of the active 
intervention and then every 3 weeks for the remainder of the 16-week intervention. At the 
16-week visit, participants are asked to continue following the diet for the final six weeks of 
the study, but without regular intensive diet counseling and research food supply. The study 
concludes at a 22-week visit in which participants undergo their final blood draw and meet 
with the study team for final assessments and unmasking (Fig. 2).
2.2.2. Modified double-blind design—A modified double-blind study design is 
applied to ensure maximal masking of participants, investigators and staff. Masking is 
maintained in the random allocation procedure, and the research staff—including 
investigators, referring and research clinicians and laboratory personnel—are masked to 
treatment assignment for the full duration of the trial. Only the dietitian, by necessity, is not 
masked in order to administer the dietary interventions. Participants receive counseling one 
at a time, not in groups; the dietitian meets with each participant individually and provides 
them with diet information on only their assigned diet. The three study diets were designed 
to produce controlled alterations in (1) n-6 LA; and (2) n-3 EPA+DHA. The diets were 
carefully designed to look and taste similar, by using as many common products as possible 
and only differing in the added visible oils and/or animal sources of fat and protein. No 
details of the other diets are provided and participants are masked to hypotheses associated 
with diet assignments throughout the study.
2.3. Intervention protocol
2.3.1. Interventions, administration, and duration—The study intervention 
consists of providing food appropriate to the study arm assignment at two and three week 
intervals, sufficient for two meals and two snacks per day for the entire 16 weeks of the 
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active intervention. In addition, participants receive in depth diet counseling by a registered 
dietitian experienced in research, reinforcing dietary choices in accordance with their arm 
assignments. They have continuous access to comprehensive web-based information on best 
food choices, grocery shopping, dining out, and detailed menus and recipes. Participants are 
asked to self-monitor their dietary intake by tracking their intake on a daily food checklist 
that targets the foods to consume regularly and the foods to avoid. Blood samples are 
collected at the start of the intervention, then at 4, 10 and 16 weeks after the start of the 
intervention, and 6 weeks post-intervention.
All participants receive: 1) tailored dietitian-administered counseling consistent with the 
group assignment; 2) access to a password-protected project website including a headache 
diary for daily completion along with intervention-specific informational materials; and 3) 
food items throughout the 16-week period of active intervention - the equivalent of two 
meals and two snacks per day - with precisely quantified fatty acid composition, formulated 
to meet nutrient intake targets specific for each of the assignment groups.
Throughout the 22 weeks of active intervention and post-intervention phases, participants 
have access to a website as a user-friendly strategy to complement and reinforce dietitian 
advice. Online diet education materials include the diet guidelines, allowed food list, how to 
read food labels, detailed grocery shopping guides for 9 local grocery stores, dining out 
guide identifying allowable foods at local restaurants, 7-day meal plan and 75 recipes with 
the ability for the dietitian to add more.
2.3.1.1. Food supply.: Each participant visits the Research Kitchen located on UNC 
campus every two to three weeks during the 16-week intervention to obtain specific food 
items with targeted nutrient compositions. Food items include cooking oils, salad dressings, 
mayonnaise, portable dressing packets, prepared snack foods, prepared breakfast foods, 
unprepared frozen food items, ingredients for home preparation of meals and snacks, and 
several packaged food items.
All foods have been formulated, or specifically selected, to ensure that participants meet 
nutrient intake targets, specific to their diet assignment. Study-provided oil blends, 
formulated to meet the diet targets, are prepared and packaged into bottles marked only with 
their diet assignment. Salad dressings and study-provided foods are prepared with the oil 
blend. Fish and poultry are specifically selected for their EPA+ DHA content. Other grocery 
staples such as frozen fruits, frozen vegetables, bread, dairy and snack foods are provided to 
encourage intake of packaged foods with added oils. Nutrient analysis of more than 80 
relevant food items is performed by the NIH-NIAAA Section of Nutritional Neurosciences 
(SNN) and used to develop the diet intervention. For foods not provided by the Research 
Kitchen, participants rely on their training by the dietitian and website diet guides for 
shopping and choosing foods in restaurants.
All intervention related visits take place in a clinical research space with adequate privacy 
and well trained, highly skilled personnel.
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Food is dispensed from the Research Kitchen located on the UNC Medical Campus. 
Portable coolers on wheels are supplied to all participants to transport food items home. 
Participants are not required to return unused food portions.
A study folder and database is maintained to document participation in all aspects of the 
project including attendance at clinic visits, maintenance of headache diary, cooperation 
with the dietitian, and reporting of adverse events.
2.4. Assessments
Participants record headache characteristics, medication use, and psychological status using 
a daily, web-based headache diary throughout the 4 to 6-week baseline phase, 16-week 
intervention phase, and the 6-week post-intervention period. Diary access and updates can 
be made using a personal computer with internet access, a smart phone, or other compatible 
portable device that connects to the internet. During times when participants do not have 
internet access they are allowed to fill out paper diaries; paper diaries are then given to study 
staff for manual data entry.
Blood samples are collected for biochemical measurement during five visits: the start of the 
intervention phase, then after 4, 10, and 16 weeks of diet exposure in the intervention, and 6 
weeks post-intervention (22 weeks). At each of these five visits, participants use the research 
clinic computer to complete the following online questionnaires: 1) Headache Impact test 
(HIT-6); 2) PROMIS-29 Profile, for assessment of anxiety, depression, fatigue, sleep 
disturbance, and physical and social role functioning; 3) The Total Pain Scale that looks at 
the comorbid pain assessment with severity index; 4) Satisfaction with Care, 5) Changes in 
Health; 6) Nicotine, Caffeine, and Alcohol scale; and 7) Hunger scale. Participants complete 
the Migraine Disability Assessment Score (MIDAS) at start of the intervention, at 
completion of the intervention phase (16 weeks), and at completion of the post-intervention 
phase (22 weeks). In addition, participants complete the Diet Acceptability Form at Weeks 
4, 10, 16, and 22.
Dietary intake is assessed by unannounced, telephone administered, 24-h dietary recalls on 
two non-consecutive days during the baseline phase and repeated during the intervention 
phase and post-intervention phase. Hence, six total 24-h dietary recall attempts are 
administered per subject by trained interviewers at the Nutritional Epidemiology Core of 
NORC and analyzed using the Nutrient Data System for Research (NDSR). Nutrient 
analyses of study foods are reconciled with the NDSR database to improve 24-h dietary 
recall accuracy.
2.4.1. Eligibility screening—Baseline evaluation for those who screen into the study 
includes headache and medical history with a physical exam and study enrollment, and 
evaluation of inclusion/exclusion criteria. During the four to six-week baseline period, 
participants who record at least five headache days and complete at least 80% of diaries are 
eligible to join the study. Participants who meet inclusion/exclusion criteria and attend the 
first intervention visit are then randomized.
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2.4.2. Baseline assessments—The 4–6 week baseline phase assessments include the 
following:
• Daily completion of the online or paper headache diary, recording hourly 
headache occurrence, intensity, duration, medication use, sleep and general 
health status;
• Two, non-consecutive 24-h dietary recall attempts;
• Vitals that include weight, height, blood pressure, pulse
• Online questionnaire that includes the following: 1) Headache Impact test 
(HIT-6); 2) PROMIS-29 Profile, for assessment of anxiety, depression, fatigue, 
sleep disturbance, and physical and social role functioning; 3) The Total Pain 
Scale that looks at the comorbid pain assessment with severity index; 4) 
Demographics; 5) Nicotine, Caffeine, and Alcohol scale; and 6) Hunger scale
2.4.2.1. Biochemical outcome measures.: The primary biochemical hypothesis is that 
plasma 17-Hydroxy DHA will increase significantly in Diet A (H3-L6) relative to the 
control diet (average US intakes of n-3 and n-6). 17-hydroxy DHA is a pathway marker and 
precursor to two families of potent bioactive mediators with anti-nociceptive properties (D 
series resolvins and protectins).
Secondary biochemical hypotheses postulate that other anti-nociceptive derivatives of EPA 
and DHA will increase and that pro-nociceptive derivatives of AA and LA will decrease in 
Diet A relative to Diet C, and that these diet-induced changes will correlate with 
improvements in pain-related clinical endpoints. Following study completion, LA, AA, EPA 
and DHA derived mediators, pathway markers and inactivation products will be quantified, 
as previously described [28]. Briefly, following protein precipitation solid phase extraction 
will be performed using a polymer-based reversed phase Strata X cartridge (33 μm, 200 
mg/6 mL, Phenomenex, PA), followed by liquid chromatography-tandem mass spectrometry 
(LC-MS/MS). The LC-MS/MS comprises a Shimadzu chromatographic system with two 
LC-20AD pumps, a SIL-20AC autosampler (4 °C), a CTO-20AC column oven (30 °C), and 
a CBM-20A controller (Shimadzu Scientific Instruments, Columbia, MD), and using a 
ZorBAX RRHD Eclipse Plus C18 column (100 mm × 4 mm; 1.8 μm). The UPLC system is 
coupled to a Qtrap 5500 mass spectrometer (AB Sciex, USA) with an electrospray 
ionization source, and operated in negative ion mode. Quantitative analysis will be 
performed using scheduled multiple reaction monitoring (sMRM) scans, with simultaneous 
profiling of targeted oxylipins derived from n-6 and n-3 fatty acids that serve as oxylipin 
precursors, as previously described [28]. A list of the oxylipins and their precursor fatty 
acids that we plan to quantify are shown in Table 3. Pathways used for biosynthesis of 
selected derivatives of LA, AA, and DHA are shown in Fig. 3. Key analytes include: 17-
hydroxy-DHA (Primary biochemical outcome; 18-HEPE (Pathway marker and precursor for 
E-series resolvins)); as well as bioactive LA-derived oxylipins (e.g. 9- and 13-HODE, 13-
hydroxy-9,10-epoxy-octadecadienoic acid, 11-hydroxy-12,13-epoxy-octadecadienoic acid); 
AA-derived eicosanoids (e.g. 5-, 12-and 15-HETE, PGE2, LTB4) and lipoxins (LXA4). In 
an exploratory manner, we will also attempt to quantify plasma concentrations of individual 
E-series and D-series resolvins, maresins, protectin D1 and other bioactive lipid mediators.
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2.4.2.2. Clinical outcome measures.
• Headache-specific Quality of Life: The Headache Impact Test (primary 
clinical outcome). (HIT–6)[29]. The HIT-6 is a validated questionnaire designed 
“to measure the impact headaches have on a person’s ability to function on the 
job, at school, at home, and in social situations” [29]. It has good internal 
reliability. The scale consists of six items that cover various content areas 
relevant to headache-related disability: pain, social functioning, role functioning, 
vitality, cognitive functioning, and psychological distress. The scores range from 
36 to 78, with higher scores indicating greater negative impact. A decrease of 2.3 
HIT points (95% CI,0.3–4.3) over six weeks among patients with chronic 
headache corresponds to a “somewhat better” self-reported rating on a global 
clinical change scale [30]. Participants complete this questionnaire at baseline, at 
the start of the intervention, at weeks 4, 10, and 16 of the intervention, and at 
week 22 of the post-intervention phase.
• Headache Diary: Frequency, Intensity, Duration. Participants are instructed to 
maintain a daily record of their headaches usinga headache diary throughout the 
entire 26 weeks of the study. This diary was used successfully in our previous 
clinical trial involving participants with chronic headache, with participants 
willing and able to complete daily diaries with minimal loss of data [27]. 
Participants record their headache duration, frequency, intensity (rating as 
“none”, “mild”, “moderate” and “severe”) and sleep for each hour of the day. 
Diaries are completed on a secure website via a computer or smart-phone 
interface. For those participants unwilling to use electronic diaries, paper diaries 
are provided. In the analyses, numbers of hours of any headache will be 
calculated along with numbers of hours of moderate to severe headache for use 
in long-itudinal models.
• Perceived Changes in Headache and Overall Health. This measure consists of 
two questions, on a Likert format scale, about participants’ perceived change 
over the last four weeks in their headache condition and overall health. Possible 
answers are much better, somewhat better, about the same, somewhat worse, 
much worse, and don’t know. This measure provides subjective outcome data 
regarding symptom change. Participants complete this brief questionnaire at the 
start of the intervention, at weeks 4, 10, and 16 of the intervention, and at week 
22 of the post-intervention phase.
• Headache–Related Disability: Migraine Disability Assessment Score 
(MIDAS). Disability, defined as the consequences of illness on ability to work 
and function, is measured using the MIDAS. Derived from the Headache Impact 
Test, MIDAS is a 7-item questionnaire that assesses the number of days during 
the previous three months that respondents missed work or school, experienced 
decreased productivity at work or home, or missed social engagements because 
of headaches [31]. Test-retest reliability is acceptable, with Spear-man’s 
correlation coefficient ranging from 0.67 to 0.73. Cronbach’s alpha is 0.83 [32]. 
The MIDAS is highly correlated with headache diaries and physician 
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assessments of patient disability and is useful for stratifying patients by degree of 
disability [33]. Participants complete this questionnaire at the start of the 
intervention, at week 16 of the intervention, and at week 22 of the post-
intervention phase.
• Headache Diary: Medication Use for Headache and Cost Analysis. 
Participants use the headache diary to record the name, dose and amount of all 
medications, including herbal remedies and supplements, taken for prevention or 
relief of headache. On the day of enrollment, the study coordinator enters the 
name and dose of each medication/supplement taken either daily or 
intermittently for headache. In the daily diary, participants choose from their list 
of medications to indicate how many doses were taken during that day. They are 
also able to add new medications to the list. In the analyses, cost for prescription 
and non-prescription medications and remedies will be estimated by pricing the 
retail cost at two local pharmacies or health food stores and averaging the result 
for each medication. The total cost of analgesic medication and total medication 
and amounts used will be calculated.
• Satisfaction with Care. At baseline, on completion of the usual-care phase and 
at the final visit, participants are asked how satisfied they have been with their 
care including, at the end of the study, their specific intervention, using a 5 point 
Likert satisfaction scale.
• Impact on Other Pain Syndromes (Whole Body Pain Scale). Participants 
indicate on this questionnaire how often in the past 7 days they have experienced 
pain in 28 anatomical sites that cover the entire body, and how much of their total 
waking time they experienced any body pain in the past 7 days. Participants 
complete this questionnaire at baseline, at the start of the intervention, at weeks 
4, 10, and 16 of the intervention, and at week 22 of the post-intervention phase.
• Patient Reported Outcomes Measurement Information System (PROMIS) 
Short Form PROMIS-29 Profile. PROMIS measures were developed from 
existing items in multiple measures of self-reported health by a collaborative 
network of researchers at the National Institutes of Health and several 
universities [34]. Using item response theory, candidate items were evaluated in 
several domains, including physical function, social functioning, psychological 
distress, pain, and fatigue and T scores were calculated for population norms 
[34]. Across all domains except fatigue, short forms of items were highly 
correlated with the full item bank (r ≥0.95) and reliability coefficients remained 
high across domains (≥0.80). Domains were correlated in expected directions 
with legacy measures (e.g., SF-36, FACIT-fatigue, Brief Pain Inventory, 
Pittsburgh Sleep Quality Index, Mood and Anxiety Symptom Questionnaire, 
FACIT-Functional Well-Being scale)[34]. Participants complete this 
questionnaire at baseline, at the start of the intervention, at weeks 4, 10, and 16 
of the intervention, and at week 22 of the post-intervention phase.
• Demographic and Clinical Characteristics. The participant’s age, gender, 
ethnicity, religion, occupation, employment status, level of education, income, 
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type of medical insurance, date of onset of headache, presence of other medical 
conditions and diagnoses are recorded at the time of the baseline interview. The 
medical history and physical exam performed by the PI become part of this data 
set. All participants are interviewed concerning their headache symptoms. 
Medical records are reviewed as needed to aid in assessing diagnostic criteria for 
the major forms of migraine using ICHD–II.
• Expectations of Benefit/Credibility. This instrument provides an assessment of 
credibility of each intervention using an adaptation of a validated credibility 
scale previously developed for psychological studies [35,36] for purposes of 
comparing the two treatment arms. This instrument has been successfully 
adapted for use in other conditions such as chronic pain and migraine headache 
[37]. It is administered at the end of the randomization visit after each subject 
receives instruction in the diet.
• Changes in Usual Care. The participants are interviewed at the start of the diet, 
at weeks 4, 10, and 16 of the intervention, and at week 22 of the post-
intervention phase to document any changes in conventional treatment that 
occurred during the study. This includes all forms of therapy for headache and 
the development of any new medical conditions or significant changes in existing 
conditions. Medical records are accessed, if necessary, with the consent of the 
participant.
2.4.2.3. Process measures.
• BiochemicalAssessment. Participants have blood drawn at the end of the 
baseline phase(the randomization visit), after 4, 10, and 16 weeks of diet 
exposure, and 6 weeks post active intervention for assessment of fatty acids, fatty 
acid derived lipid mediators, pathway markers and inactivation products, and 
other bioactive mediators and biomarkers that may be altered by the study diets. 
Blood samples are collected by a Clinical Translation Research Center (CTRC) 
phlebotomist, immediately processed to plasma and erythrocytes by the study 
coordinator, barcoded and immediately stored in a −80 °C freezer, and 
transferred to the Bioanalytical Core Laboratory. At completion of the study, 
batched plasma samples will be delivered to the NIH/NIA Lipid Mediators, 
Inflammation and Pain Unit, Laboratory of Clinical Investigation and for 
analysis of precursor fatty acids, lipid mediators, pathway markers and 
inactivation products. Other biochemical assessments will be performed through 
the UNC Bioanalytical Core Laboratory, using ELISA methodology.
• Erythrocyte Fatty Acids. Fasting (>10 h) blood are collected at the conclusion 
of the run-inphase, and after 4, 10, and 16-weeks of diet exposure and at 6 weeks 
post-intervention (Week 22), in EDTA tubes and immediately centrifuged at 
2960 rpm for 15 min. Erythrocyte aliquots are prepared and stored at −80 °C 
until analysis. Following Bligh/Dyer extraction [38], aliquots are heated at 
100 °C for one hour with methanol containing 14% boron trifluoride to generate 
FAME, which is then extracted into hexane and analyzed with a GC/FID gas 
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chromatograph (Agilent 6890) equipped with a 30-m DBFFAP capillary column. 
Fatty acids are identified through comparison with a fatty acid methyl ester 
mixture (GLC-462) and reported as individual fatty acids. Two composite fatty 
acid indices (Harris 2009; Stark 2008) [39,40] are also calculated. The n-6 in 
HUFA score is equal to the proportion of n-6 fatty acids in total highly 
unsaturated fatty acids (HUFA). The n-3 Index is equal to the sum of erythrocyte 
n-3 EPA and DHA as a percent of total fatty acids.
• Dietary Intake Assessment. Nutrient intake data is collected during each phase 
of the study via two telephone administered 24-h dietary recalls on non-
consecutive days – one weekend day and one weekday. Calls are conducted by 
trained research staff of the UNC Nutrition and Obesity Research Center’s Diet 
and Physical Activity Core (DK56350) using the standard multiple pass 
interviewing method. Analysis is performed using Nutrient Data System for 
Research (NDSR) software developed by the Nutrition Coordinating Center, 
University of Minnesota, Minneapolis, MN, Food and Nutrient Database. 
Integration of 24-h dietary recalls and the NDSR software generates estimates of 
daily consumption of 155 nutrients and other variables (www.ncc.umn.edu/
products/database.html). The food and nutrient dataset includes approximately 
18,000 foods. A total of six 24-h dietary recall assessments take place during the 
26-week study period. Pre-intervention nutrient intakes are calculated from 24-h 
dietary recalls performed during the 4–6 weeks of the baseline period. The same 
procedure is performed in the final 6 weeks of the 16-week active intervention 
period, allowing for comparison of pre- and post-intervention nutrient 
consumption. Finally, the same procedure (2 more non-consecutive 24-h dietary 
recalls) is repeated in the final 6 weeks of the 6-week post-active intervention 
period. The goal of the final recalls is to determine whether participants are able 
to continue the diets without provision of the food. The NDSR database is 
updated with information derived from study recipes and the NIAAA nutrient 
analyses of study-provided foods.
• Diet Acceptability Form (Acceptability of Experimental Diets): This 
instrument has been developed for this study to assess satisfaction and 
acceptability regarding the prescribed diet and will be evaluated for its 
psychometric properties. An appropriate instrument with known psychometric 
properties with which to assess systematically the acceptability of specific diets 
could not be identified in the literature. The Diet Acceptability Form consists of 
a series of questions (5 simple questions plus open-ended query), assessing 
participant’s satisfaction with their assigned diet. The instrument is not designed 
to assess aspects of the diet that the participants found unsatisfactory, but rather, 
is intended as a metric to estimate the likelihood that the participant would be 
willing and able to adhere to the diet. The format for the questions are based on 
the Diabetes Quality of Life Measure for the Diabetes Control and 
Complications Trial [41] with the response options “Strongly Agree, Agree, 
Disagree, or Strongly Disagree”. Participants complete this online questionnaire 
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during four visits after randomization at weeks 4, 10, and 16 of the intervention, 
and at week 22 of the post-intervention.
Outcomes are listed within the Schedule of Evaluations shown in Fig. 3.
2.5. Statistical analysis
2.5.1. Sample size and randomization—The sample size was selected based on 
expected available funding and the resources of the Research Kitchen over 5 years. Power 
was calculated for the available sample size (Table 4).
The primary biochemical hypothesis is that the H3-L6 intervention (Diet A) will result in 
significantly higher levels of 17-Hydroxy DHA than the control L3-H6 intervention (Diet C) 
as measured after 16 weeks of the dietary intervention. In the previous study, 17-Hydroxy 
DHA increased significantly (by 0.9 lnNm, p = 0.0001) in the Diet A group (n = 33) relative 
to the comparator (n=34). Power for the present study was calculated for an overall 
difference (ANOVA) using an alpha of 0.05 and for between group comparisons using 
contrasts with a Bonferroni-corrected alpha of 0.0167. Since repeated measures are 
available, we also estimated the power based on the rate of change in 17-Hydroxy DHA 
using assumptions based on the Chronic Daily Headache trial. We expect to have ample 
power to test the overall difference among groups and the contrast between Diet A and the 
control diet. Estimates for Diet B are unknown; this study will provide important 
information regarding effect sizes for Diet B, enabling future research to address this 
question more fully.
Power analysis is also provided for the primary clinical outcome, the Headache Impact Test 
(HIT-6). Relative to the control diet, the HIT-6 in Diet A is hypothesized to show a 
significant reduction post-intervention. In our previous diet trial in participants with CDH, 
the HIT-6 for the Diet A group improved by a mean of 7.5 points (in an ITT analysis 
assuming no change in scores of participants who dropped after randomization) compared 
with a drop of 2.0 points in the comparator diet (p = 0.01, based on ANCOVA model 
controlling for baseline). Power for the present study was calculated for an overall difference 
(ANOVA) using an alpha of 0.05 and for between group comparisons using contrasts with a 
Bonferroni-corrected alpha of 0.0167.
Based on our previous research experience we estimate the drop-out rate to be 20–30% prior 
to randomization. With this drop-out rate, we need to recruit at least 191 participants into the 
baseline phase. Our drop-out rate in the intervention phase, post randomization, is estimated 
at 15–20%. If participants drop out early in the intervention period, new participants will be 
enrolled, potentially increasing the effective sample size for intention-to-treat (ITT) analysis. 
The analysis will retain all randomized participants for ITT analysis. To reduce selection 
bias, missing data post-randomization will be imputed using multiple imputation procedures. 
Participants who violate protocol (e.g., consume fatty fish while on Diet C) will be retained 
in their randomized group for analysis. In addition to the ITT analysis, we will complete an 
exploratory per protocol analysis, removing participants from the analysis who withdraw 
from the study or are not compliant with the protocol.
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In this randomized study, only exploratory analysis of subgroups is planned, taking effect 
modification into consideration; sample size is not adjusted for interaction effects.
2.6. Definition of populations
We are defining our intention-to-treat population as all participants who are randomized. We 
will retain randomized participants in the groups to which they were randomized. For a per 
protocol analysis, we will analyze data from participants who attend all study visits and 
complete at least 80% of their diary data.
2.7. Interim analyses and stopping rules
We are not planning any pre-specified interim analyses for any reason. The study may be 
suspended by our PI or the Data and Safety Monitoring Board (DSMB) if a severe adverse 
event occurs that is deemed to be secondary to one of the dietary interventions. The DSMB 
may also suspend or stop the study or a study arm if reported adverse events are increasing, 
either across all intervention arms or in a particular study arm.
2.8. Outcomes
Outcomes include biochemical measures (analyzed at NIH/NIA) and self-reported clinical 
outcomes. All self-report measures are entered into an electronic database directly by 
participants. The study coordinator verifies complete data entry after each study visit.
2.9. Data analyses
This study is a three-arm intervention trial with a baseline measurement and repeated 
measures of the outcome variable over time. A descriptive analysis will be conducted to 
report the observed outcome differences in treatment groups and to check outliers in the 
data. Regression analyses will be performed to examine all stated specific aims. Because of 
the multiple arms in the design of the study, we will first assess a global test of no difference 
in the outcome in the three arms and, if found significant, will conduct pair-wise group 
comparisons with a Bonferroni-adjusted level of significance. All models will include an 
indicator variable for study recruitment site.
2.9.1. Primary biochemical outcome—Change in plasma 17-hydroxy DHA—this 
analysis will utilize the baseline and 16-week measure of 17-hydroxy DHA. We will 
transform the variable as needed to achieve normality. We will construct an analysis of 
covariance model with the 16-week ln(17-hydroxy DHA) as the outcome and indicator 
variables for the two treatment arms (β1 and β2) with the baseline ln(17-hydroxy DHA) as a 
control variable. Study site (0 for Site 1, 1 for Site 2) will be added as an additional control 
variable. First, we will test the hypothesis that β1 = β2 = 0 with a partial F test. If this test is 
statistically significant at the α = 0.05 level, we will test the pairwise comparisons, using 
Bonferroni corrections.
2.9.2. Primary clinical outcome—Change in HIT-6—this analysis will also use the 
baseline and 16-week measures and a similar statistical procedure. The HIT-6 is usually 
normally distributed.
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2.9.3. Longitudinal model for primary outcomes—Trajectory of change for plasma 
17-hydroxy DHA—we expect to be able to transform the data successfully to enable us to 
maintain the variables as continuous. In this linear mixed model, the measurement of each of 
the fatty acid derivatives at specific times will be the dependent variable. Fixed effects will 
include the independent variables, the allocated diets (treatments), time, the treatment* time 
variables and the recruitment site. Random effects will include participants. Significant 
regression coefficients of the interaction terms will indicate that the rate of change in the 
fatty acid derivatives differ by treatment assignment. We will use the SAS procedure 
MIXED (or GLIMMIX) to estimate the model and test hypotheses (SAS Institute, Inc., Cary 
NC). A test of global hypothesis of no treatment effect will be the joint hypothesis that the 
regression coefficients of the two treatment*time coefficients are zero. If this global test is 
rejected, we will conduct pair-wise comparisons with Bonferroni adjustments. Model fitting, 
including choice of covariance structure, will depend on comparisons of the Aikake 
Information Criteria. A similar approach will be applied to the long-itudinal HIT-6 analysis.
2.9.4. Longitudinal models for diary data—Trajectory of change in headache hours 
per day and severe head ache hours per day over the 16 weeks of the intervention—we will 
extract this information from the diary as summary measures. These measures are available 
for a baseline phase of 4–6 weeks, and an intervention phase of 16 weeks, and a post-
intervention phase of 6 weeks (varies among individuals). We will treat the outcome 
measure as a repeated count variable (number of headache hours). Because the outcome 
measures for an individual are correlated, we will fit Poisson regression models using a GEE 
approach. The treatment indicators, time, and time*treatment will be used as independent 
variables. The significance of interaction variables will determine whether the change in 
headache hours depends on the diet group. It is expected that there will be a large number of 
zero headache hours in the data. To take this into account, we will include an over-dispersion 
parameter in the model and assess the fit of alternative distributions (zero-inflated Poisson, 
negative binomial zero-inflated Poisson) and alternative models (subject-specific random 
effects model). If the severe headache hours’ model does not demonstrate adequate fit 
parameters, we will model the probability of a severe headache day, defined as a day with at 
least 8 h of mild headache or any hour of a moderate or severe headache.
In the analysis, we anticipate using a linear (or quadratic) spline variable with cut points at 
the day of randomization and the day of the last intervention visit. This will allow us to 
model the slope of Headache Hours per day over the three time periods of the study—
baseline, intervention, and post-intervention. We will also create graphical displays of mean 
headache hours per day and severe headache hours per day by intervention group to 
facilitate visualization of the results. We anticipate using a Loess graphical smoothing 
procedure for this display.
2.9.5. Secondary clinical outcomes—Pre- to post-intervention and trajectory of 
change assessments of secondary clinical outcomes (e.g., MIDAS, PROMIS measures, total 
pain score, cost of care) will be similar to the primary clinical outcome.
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2.9.6. Secondary biochemical outcomes—Pre- to post-intervention and trajectory 
of change for n-6 and n-3 free precursor fatty acids, lipid mediator derivatives and pathway 
markers. Analysis will be similar to Outcome 1 and Outcome 3.
2.9.7. Process measures—1) erythrocyte EPA, DHA, LA, and AA collected at the 
randomization visit and at 4, 10, 16, and 22 weeks after randomization; and 2) two 24-h 
dietary recalls by telephone in the baseline phase, between weeks 10 and 16 post-
randomization, and between weeks 16 and 22 post-intervention. We will calculate mean and 
median values for erythrocyte EPA, DHA, LA, and AA by intervention group at each time 
point. Similarly, we will calculate mean and median intakes of dietary EPA, DHA, LA, and 
AA from the 24-h dietary recall using established methods (nonlinear mixed effects model 
with Box Cox transformation) to assess usual intakes [42,43].
2.9.8. Subgroup analyses—To assess effect modification in the above analyses, we 
will add interaction terms for age and race to the models. For example, for the primary 
biochemical outcome, we will test the contribution of the interaction between treatment and 
sex and treatment and race. The importance of interaction terms will be tested by removing 
the variables and running a likelihood ratio test. If the interaction terms add significantly to 
the analysis, we will present stratified results.
2.9.9. Exploratory analyses—In this analysis, we hypothesize that changes in the 
RBC fatty acids (Fig. 4, Pathway 6) and their lipid mediator derivatives (Fig. 4, Pathway 4) 
will result in significant improvements in headache-specific quality-of-life and headache 
frequency and duration. In the first analysis, the HIT-6 will be the outcome with each (log-
transformed) RBC fatty PUFA as independent variables in a linear regression model. We 
will also test a model with combined EPA/DHA and LA to assess the impact of LA in the 
model while controlling for changes in n-3 fatty acids. A similar approach will test the 
influence of the fatty acid derivatives on the HIT-6 outcome. Analysis of headache 
frequency/duration (headache hours per day) will employ a longitudinal Poisson regression 
model as described in the Outcome 5 analysis section. Available data will also allow us to 
test for mediation effects on the HIT-6 outcome. We can test the linear regression of dietary 
EPA + DHA intakes on the HIT-6 score and add RBC PUFAs to the model. If significant 
mediation is present, we should see a marked decrease in the effect estimates associated with 
EPA + DHA intakes. A similar analysis will test mediation of fatty acid derivatives on RBC 
PUFA effects on the HIT-6.
3. Results
3.1. Progress on study
Current enrollment for the study (as of March 31, 2017) has totaled 214 participants. To 
enroll that number, the study team has contacted 1151 potential participants. Participants are 
primarily recruited from neurology clinics in Chapel Hill, Raleigh, and Durham area as well 
as from the UNC community. Stakeholder engagement with the clinics have been critical to 
maintain patient referral for the study. Study team members check in or visit each clinic site 
every other week to keep referring providers and clinic personnel engaged in the project. In 
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addition to provider engagement, study flyers and brochures are posted within the clinic 
areas to engage patients as well as around the UNC community. To keep recruitment steady, 
recruitment emails are sent through the university’s mass emailing system every 2–4 
months.
Of the 214 screened and enrolled to date, 141 have been randomized. We anticipate having 
our target number randomized by December 2017.
Most adverse events and unanticipated problems have been unrelated to the study 
intervention. One participant who had prior gastric bypass surgery was unable to stay on the 
study diet and had to withdraw from the study, which should be taken into consideration as a 
possible exclusion criterion for diets such as the ones tested in this study. Also, participants 
with gallstones or gall bladder removal may have difficulties adjusting to the diet; therefore, 
future studies may want to consider these as exclusion criteria or carefully screen 
participants, as they may have issues with fatty diets as well.
4. Discussion
Episodic migraine is a debilitating chronic pain condition afflicting 12% of American adults. 
Current conventional treatments rely on medications that provide limited or transient relief, 
target symptoms rather than the underlying causes of pain, and are associated with 
significant side effects and costs. It is therefore important to investigate non-pharmacologic 
approaches to conventional headache treatments.
Omega-6 (n-6) and omega-3 (n-3) fatty acids regulate multiple pain-related biochemical 
pathways. Controlled clinical trials investigating pain modulation in response to dietary 
changes while exploring relevant mechanisms of action in humans are lacking. This protocol 
utilizes an innovative design and hypotheses to examine clinical efficacy and underlying 
mechanisms of a promising dietary manipulation with the distinct potential for high impact 
in terms of ameliorating a chronic, disabling pain disorder.
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Fig. 3. Biosynthetic pathways converting dietary and membrane n-6 and n-3 fatty acids to lipid 
mediators of inflammation and pain.
(A) LA converted by lipoxygenases to 9-HpODE can reduced by glutathione peroxidases to 
9-HODE, or converted via hydroperoxide isomerization to generate hydroxy-epoxide and 
keto-epoxide LA derivatives. LA can be converted to 9,10-EpOME and 9,10-DiHOME by 
the actions of cytochrome P450 epoxygenases and soluble epoxide hydrolase, respectively. 
HODEs, EpOMEs, and hydroxy-epoxide LA derivatives modulate pain responses in 
preclinical models. (B) Arachidonic acid can be converted by cyclooxygenases to generate 
prostanoids including PGE2, or by lipoxygenases to form leukotrienes and lipoxins. 
Prostanoids evoke pain in human trials; leukotrienes and lipoxins modulate pain responses in 
preclinical models. (C) Docosahexaenoic acid can be converted by 12-lipoxygenase to 
generate maresins, or by 15-lipoxygenase to generate resolvins and protectins. These 
specialized pro-resolving mediators have anti-nociceptive properties in pre-clinical models. 
Abbreviations; LA, linoleic acid, HpODE, 9-hydroperoxy-octadecadienoate; HODE, 
hydroxy-octadecadienoate; oxo-ODE, oxo-octadecadienoate; EpOME, epoxy-
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octadecenoate; DiHOME, dihydroxy-octadecenoate; PGE2 prostaglandin E2; DHA, 
docosahexaenoic acid; HpDHA, hydroperoxy—DHA; HDHA, hydroxy-DHA.
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Schematic model linking dietary PUFA intakes to headache outcomes.
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Table 3





DPA n-6 22:5 n-6
ALA 18:3 n-3
EPA 20:5 n-3
DPA (n-3) 22:5 n-3
DHA 22:6 n-3
EPA + DHA 20:5n-3 + 22:6n-3
Palmitic acid. 16:0








13-hydroxy-9,10-epoxy octadecadienoic acid LA
11-hydroxy-9,10-epoxy octadecadienoic acid LA
9-hydroxy-12,13-epoxy octadecadienoic acid LA










17-hydroxy-DHA (precursor to D-series resolvins) DHA
18-HEPE (precursor to E-series resolvins) EPA
Lipoxins A4 AA
D-series Resolvins DHA
D- and E-series Resolvins DHA, EPA
Maresins DHA
Abbreviations: LA linoleic acid; AA arachidonic acid; DTA docosatetraenoic acid; DPA docosapentaenoic acid; ALA alpha-linolenic acid; EPA 
eicosapentaenoic acid; DHA docosahexaenoic acid; HODE hydroxy-octadecadienoic acid; oxoODE oxo-octadecadienoic acid; EpOME, epoxy-
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octadecenoic acid; HETE hydroxy-eicosatetraenoic acid; oxo-ETE oxo-eicosatetraenoic acid; HEPE, hydroxy-eicosapentaenoic acid; PG 
prostaglandin; LT leukotriene; TX thromboxane.
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